Hispanic Broadcasting Newswire

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 94 in Hispanic Broadcasting

  1. Arkansas execution drug likely from Pfizer unitRead the original story w/Photo

    Monday Jul 25 | St. Augustine Record

    An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. The sale of the vecuronium bromide by an unknown third party may show how difficult it could be for manufacturers to prevent such sales in states like Arkansas that have execution secrecy laws.

    Comment?

  2. APNewsBreak: Pfizer: Arkansas execution would 'misuse' drugRead the original story

    Monday Jul 25 | The Gazette

    An execution drug obtained by the Arkansas prison system this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. The sale of the vecuronium bromide by an unknown third party may show how difficult it could be for manufacturers to prevent such sales in states such as Arkansas that have execution secrecy laws.

    Comment?

  3. En Banc CAFC Requires UCC Sale For On Sale BarRead the original story w/Photo

    Friday Jul 22 | jdsupra.com

    In an en banc decision issued in The Medicines Company v. Hospira, Inc. , the Federal Circuit determined that in order for a commercial transaction to trigger the on-sale bar of 35 USC 102 , it must "bear the general hallmarks of a sale pursuant to Section 2-106 of the Uniform Commercial Code."

    Comment?

  4. Fresenius Bid for Pfizer's Pumps Unit Said to Stall on ValuationRead the original story

    Thursday Jul 21 | The Washington Post

    Fresenius SE's negotiations to acquire Pfizer Inc.'s pumps and devices business have stalled on valuation, according to people with knowledge of the matter. Pfizer has decided to resume talks with private equity firms to try for a more attractive price for the business, which it acquired in last year's purchase of Hospira Inc., two of the people said, asking not to be identified because the deliberations are private.

    Comment?

  5. Lowered Risk for Inventors Who Use Contract Product Development or ManufacturingRead the original story w/Photo

    Tuesday Jul 19 | JD Supra

    On July 11, in The Medicines Company v. Hospira, Inc. , the Federal Circuit held that a contract manufacturer's sale of manufacturing services to an inventor did not constitute a commercial sale of the patented invention for purposes of the "on-sale bar," a provision which prohibits the patentability of an invention that has been for sale for over one year prior to the patent filing.

    Comment?

  6. Federal Circuit Helps Clarify What Constitutes a Commercial Sale under PfaffRead the original story w/Photo

    Tuesday Jul 19 | JD Supra

    In The Medicines Co. v. Hospira Inc ., Appeal No. 2014-1469 , the Federal Circuit issued a unanimous en banc decision ruling that the on-sale bar was not triggered by a supplier's sale of manufacturing services to an inventor largely because the title to the invention and the right to market the invention never passed from the inventor to the supplier.

    Comment?

  7. Federal Circuit Rules for The Medicines Company in Patent LitigationRead the original story w/Photo

    Monday Jul 18 | JD Supra

    In an en banc decision on July 12, 2016 in The Medicines Co. v. Hospira, Inc ., the Federal Circuit established the circumstances under which a product manufactured according to product-by-process claims is invalid under the "on sale" bar of 35 U.S.C. 102 .

    Comment?

  8. En Banc Federal Circuit Rules A Product Must be the Subject of a...Read the original story w/Photo

    Friday Jul 15 | JD Supra

    On July 11, 2016, the U.S. Court of Appeals for the Federal Circuit ruled in a unanimous en banc decision in The Medicines Co. v. Hospira Inc. , Federal Circuit case number 2014-1469, that to be "on sale" under pre-AIA 35 U.S.C. 102 , a product must be the subject of a commercial sale or offer for sale, and that a commercial sale is one that bears the general hallmarks of a sale pursuant to Section 2-106 of the Uniform Commercial Code.

    Comment?

  9. En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract ManufacturersRead the original story w/Photo

    Thursday Jul 14 | jdsupra.com

    Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the mere sale of manufacturing services to create embodiments of a patented product is not a "commercial sale" of the invention that triggers the on-sale bar of 35 U.S.C. 102 . [1] The en banc opinion in The Medicines Company v.

    Comment?

  10. Federal Circuit Clarifies the "Commercial Offer for Sale" Prong of the On-Sale BarRead the original story w/Photo

    Thursday Jul 14 | JD Supra

    On July 11, 2016, a unanimous Federal Circuit en banc affirmed that The Medicines Company's use of third-party contract manufacturing services did not invalidate U.S. Patent Nos. 7,582,727 and 7,598,343 under the on-sale bar, reverting back to the district court's original ruling but on modified grounds.

    Comment?

  11. Federal Circuit Limits On-Sale Bar's ReachRead the original story w/Photo

    Thursday Jul 14 | JD Supra

    If you were concerned that outsourcing the manufacture of your invention before you filed your patent application triggered a "sale" that could put your patent at risk, you can rest easy. In The Medicines Company v.

    Comment?

  12. Federal Circuit Finds That Use of a Contract Manufacturer Does Not Trigger the On-Sale Bar ProvisionRead the original story w/Photo

    Thursday Jul 14 | jdsupra.com

    On July 11, in The Medicines Co. v. Hospira, Inc. , No. 14-1469 , the U.S. Court of Appeals for the Federal Circuit narrowed the reach of the "on-sale bar" under 35 U.S.C. 102 as it applies to both product and product-by-process claims.

    Comment?

  13. No Sale: Unanimous Federal Circuit Says "Commercial...Read the original story w/Photo

    Wednesday Jul 13 | JD Supra

    On July 11, 2016, in The Medicines Co. v. Hospira, Inc. , the en banc Federal Circuit unanimously concluded that "to be 'on sale' under 102 , a product must be the subject of a commercial sale or offer for sale, and that a commercial sale is one that bears the general hallmarks of a sale pursuant to Section 2-106 of the Uniform Commercial Code."

    Comment?

  14. Federal Circuit Defines Commercial Sale For 'On-Sale' BarRead the original story w/Photo

    Wednesday Jul 13 | JD Supra

    Unanimous en banc Federal Circuit holds that on-sale bar only applies where a commercial sale "bears the general hallmarks of a sale." On July 11, in a unanimous en banc ruling, the full US Court of Appeals for the Federal Circuit vacated a panel decision that The Medicines Company's patents were invalid under Section 102 because its blood-thinning Angiomax product was "on sale" one year before the filing of the patent applications.

    Comment?

  15. The Medicines Company v. Hospira, Inc.Read the original story w/Photo

    Wednesday Jul 13 | JD Supra

    The past decade or so of U.S. patent law has been characterized by a consistent theme between Federal Circuit decisions and the Supreme Court's invalidation of them . This theme is that the Court has had to intervene to prevent the Federal Circuit from establishing "bright-line" rules in patent cases, or in too stringently applying even those rules that would otherwise be capable of being implemented with sufficient flexibility to pass Supreme Court muster.

    Comment?

  16. The Medicines Company, Plaintiff-Appellant v. Hospira, Inc., Defendant-Cross-AppellantRead the original story w/Photo

    Monday Jul 11 | FindLaw

    Before PROST, Chief Judge, NEWMAN, LOURIE, DYK, MOORE, O' MALLEY, REYNA, WALLACH, TARANTO, CHEN, HUGHES, and STOLL, Circuit Judges. EDGAR HAUG, Frommer Lawrence & Haug LLP, New York, NY, argued for plaintiff-appellant.

    Comment?

  17. Federal Circuit Rules For The Medicines Company In Angiomax (Bivalirudin) Patent LitigationRead the original story

    Monday Jul 11 | BioSpace

    The Medicines Company announced that the U.S. Court of Appeals for the Federal Circuit Court, in an en banc review, unanimously affirmed the earlier district court ruling in The Medicines Company v. Hospira, Inc. , finding that the Company's Orange Book patents covering AngiomaxA that expire in 2028 were not invalid under the "on sale" bar.

    Comment?

  18. Pfizer to close Boulder facility, eliminate 100 jobsRead the original story w/Photo

    Jun 23, 2016 | Denver Post

    The Pfizer headquarters in New York City stands in the heart of Manhattans business district on October 29, 2015 in New York City. Drug maker Pfizer Inc. said Wednesday it would shutter its Boulder production facility at 4876 Sterling Drive, eliminating 100 jobs.

    Comment?

  19. 100+ Jobs Gone as Pfizer to Shut Down Boulder FacilityRead the original story

    Jun 22, 2016 | BioSpace

    Drug maker Pfizer Inc. said Wednesday it would shutter its Boulder production facility at 4876 Sterling Drive, eliminating 100 jobs in the process. Pfizer, which acquired the facility last year when it purchased Hospira Inc., said it had determined, in an analysis, that the facility was being under utilized, according to Pfizer Spokeswoman Joan Campion.

    Comment?

  20. Pfizer to close Boulder facilityRead the original story w/Photo

    Jun 22, 2016 | Daily Camera

    Drug maker Pfizer Inc. said Wednesday it would shutter its Boulder production facility at 4876 Sterling Drive, eliminating 100 jobs in the process. Pfizer, which acquired the facility last year when it purchased Hospira Inc., said it had determined, in an analysis, that the facility was being under utilized, according to Pfizer Spokeswoman Joan Campion.

    Comment?